Conditions Affecting HbA1c Accuracy and Polydipsia Diagnosis

Conditions That Falsely Lower HbA1c

• Hemolytic anemias shorten red blood cell lifespan, reducing glucose exposure time and causing HbA1c to underestimate true glycemic control, according to the American Diabetes Association 1, 2, 3
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency can decrease HbA1c by 0.7-0.8% in homozygous individuals, making glycemic control appear better than reality, as reported by the American Diabetes Association 1, 2, 3
• Sickle cell disease or sickle cell trait makes HbA1c measurement unreliable due to altered red cell turnover, as stated by the American Diabetes Association 1, 2, 3
• Recent blood loss, hemorrhage, or blood transfusion within the past 2-3 months can falsely lower HbA1c, according to the American Diabetes Association 1, 2, 3
• Hemodialysis and end-stage kidney disease cause HbA1c to underestimate glycemic exposure, as reported by the National Kidney Foundation 4, 2, 3
• Erythropoietin therapy falsely lowers HbA1c readings, according to the American Diabetes Association 2, 3, 5

Diagnostic Considerations

• If any conditions that falsely lower HbA1c are present, obtain fasting plasma glucose and/or 2-hour oral glucose tolerance test to confirm true glycemic status, as recommended by the American Diabetes Association 2, 3, 6
• Verify HbA1c accuracy by obtaining complete blood count to assess for anemia or conditions affecting red cell turnover, as suggested by the American Diabetes Association 3, 5
• Consider hemoglobin electrophoresis if variant suspected, according to the American Diabetes Association 2, 3
• Confirm glycemic status if HbA1c potentially unreliable by obtaining fasting plasma glucose and 2-hour oral glucose tolerance test, as recommended by the American Diabetes Association 2, 3, 6
• Fasting glucose ≥126 mg/dL or 2-hour glucose ≥200 mg/dL confirms diabetes regardless of HbA1c, according to the American Diabetes Association 1, 2
• Check serum calcium, potassium, and creatinine to identify metabolic causes, as recommended by the American Diabetes Association 2

Critical Pitfalls to Avoid

• The most dangerous error is accepting a normal HbA1c at face value in a patient with polydipsia without first ruling out conditions that falsely lower HbA1c, as warned by the American Diabetes Association 2, 3
• Always obtain direct glucose measurements (fasting glucose or OGTT) when clinical suspicion for diabetes is high despite normal HbA1c, as recommended by the American Diabetes Association 2, 3, 6

Monitoring Glycemic Control in G6PD Deficiency

Introduction to G6PD Deficiency and Glycemic Control

• The American Diabetes Association identifies G6PD deficiency as a condition that interferes with HbA1c accuracy, making it an unreliable measure for glycemic control in affected patients 7

Recommended Monitoring Strategy

• The American Diabetes Association recommends using continuous glucose monitoring (CGM) as the preferred method for assessing glycemic control in G6PD deficiency, as it provides real-time glucose data without reliance on red blood cell turnover 8, 9, 7
• CGM provides time in range (TIR), time below range (TBR), and time above range (TAR) metrics that correlate with microvascular complications, with a recommended target of minimizing time below and above range 10, 7
• The glucose management indicator (GMI) can be calculated from CGM data as: GMI (%) = 3.31 + 0.02392 × [mean glucose in mg/dL], serving as an alternative to HbA1c for treatment decisions 9
• Factory-calibrated CGM systems, such as Abbott FreeStyle Libre and Dexcom G6, are preferred because they do not require fingerstick calibrations that could be affected by G6PD-related hemolysis 9, 11

Alternative Glycemic Marker: Fructosamine

• Fructosamine is a reliable alternative to HbA1c, reflecting glycemia over 2-4 weeks and not affected by red blood cell turnover, with a target of <250 µmol/L to prevent microvascular complications 8, 10, 12
• Fructosamine assays should be adjusted for serum albumin levels, as hypoalbuminemia can bias results high 8

Adjunctive Monitoring: Self-Monitoring of Blood Glucose

• Self-monitoring of blood glucose (SMBG) should be used with glucose oxidase-based or hexokinase-based meters, avoiding GDH-PQQ-based meters due to potential interferences 8, 13
• The frequency of SMBG should match treatment intensity, with recommendations for multiple daily injections or insulin pump therapy requiring 6-10 checks daily 13, 10

Critical Considerations

• Methylene blue should be avoided in G6PD deficiency, as it is ineffective and can worsen hemolysis 14
• In populations with high G6PD prevalence, screening for G6PD genotype when using HbA1c for diabetes diagnosis can help avoid missed diagnoses, although this specific recommendation is not directly cited, the importance of considering G6PD status in diagnostic approaches is emphasized throughout the guidelines 7, 8

Diagnostic Use of Hemoglobin A1C for Diabetes Mellitus

1. Evidence‑Based Rationale

• The American Diabetes Association (ADA) states that hemoglobin A1C reflects average glycemia over the preceding 2–3 months and correlates directly with microvascular complications, especially diabetic retinopathy at the 6.5 % threshold【15】【16】.
• The 6.5 % A1C cut‑off marks the inflection point where retinopathy prevalence rises, mirroring the diagnostic thresholds of fasting plasma glucose ≥ 126 mg/dL and 2‑hour OGTT ≥ 200 mg/dL【15】【16】.
• Consequently, an A1C ≥ 6.5 % identifies individuals at the glycemic level at which microvascular damage begins【16】.

2. Practical Advantages Over Glucose Testing

• No fasting required, eliminating a major barrier to test completion【15】【16】.
• Greater pre‑analytical stability of whole‑blood specimens reduces degradation before analysis【15】【16】【17】.
• Reduced day‑to‑day variability during acute stress, illness, or other transient conditions compared with single glucose measurements【15】【16】【17】.
• Provides a measure of chronic glycemia rather than a single point value, offering a more comprehensive metabolic picture【15】【16】.
• The ADA notes that although A1C ≥ 6.5 % detects about one‑third fewer cases than fasting glucose ≥ 126 mg/dL in universal screening, its convenience may increase overall diagnoses because more patients complete the test【16】【17】.

3. Standardization of A1C Assays

• Historical concerns about assay variability have been resolved: A1C testing is now highly standardized through the National Glycohemoglobin Standardization Program (NGSP) and traceable to the Diabetes Control and Complications Trial (DCCT) reference method, ensuring uniform results across laboratories and over time【15】【16】【17】.

4. Situations in Which A1C Is Unreliable (Use Glucose Criteria)

All of the above conditions require exclusive reliance on glucose‑based criteria【15】【16】【17】.

5. Rapidly Evolving Type 1 Diabetes

• In acute‑onset type 1 diabetes, A1C may remain normal because the disease progresses faster than the 2–3‑month averaging period; a random plasma glucose ≥ 200 mg/dL with classic symptoms confirms the diagnosis immediately【15】【16】【17】.

6. Diagnostic Algorithm for Adults

• Screening asymptomatic adults: A1C ≥ 6.5 % is diagnostic provided the test is performed in an NGSP‑certified laboratory【15】【16】【17】.
• Confirmation: Repeat testing is recommended unless overt clinical hyperglycemia is evident【15】【17】.
• When to revert to glucose testing: Any condition affecting red‑cell turnover, pregnancy, or acute hyperglycemic presentation (random glucose ≥ 200 mg/dL) mandates fasting glucose ≥ 126 mg/dL or 2‑hour OGTT ≥ 200 mg/dL【15】【16】【17】.

7. Interpretation of Discordant Results

• If A1C and glucose tests disagree, repeat the test that is above its diagnostic threshold to confirm the result【17】.
• When both A1C ≥ 6.5 % and glucose criteria are met on initial testing, diabetes is confirmed even if the values are not perfectly aligned【17】.

8. Assay Considerations

• Point‑of‑care A1C devices lack sufficient accuracy for diagnostic use and should be avoided【15】【16】【17】.
• For patients with hemoglobinopathies but normal red‑cell turnover (e.g., sickle‑cell trait), employ an interference‑free A1C assay validated for such variants【15】【16】【17】.

All statements are derived from ADA‑endorsed guidelines and peer‑reviewed evidence published in Diabetes Care (2010‑2014). The strength of evidence is based on expert consensus and high‑quality observational data where explicit grading was not provided.